Search
SPL23-2
go.drugbank.com/drugs/DB17866ExperimentalSPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]
TTX-MC138
go.drugbank.com/drugs/DB18628InvestigationalTTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.
ISF402
go.drugbank.com/drugs/DB06315ExperimentalISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.
Milveterol
go.drugbank.com/drugs/DB05043InvestigationalGSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalDaridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity. … Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin signalling pathway in wakefulness and [almorexant], an orexin receptor antagonist that improved
Talizumab
go.drugbank.com/drugs/DB05797ExperimentalTNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Mestranol
go.drugbank.com/drugs/DB01357ApprovedWithdrawnThe 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.
Liotrix
go.drugbank.com/drugs/DB01583ApprovedLiotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was...
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous...